FDAapproval83% confidence
Competitive Generic Therapy Approvals
Source: FDA
Why This Matters
Why this matters: sets a approval precedent in the same sub-indication (her2) as Enhertu recommended for EU approval in HER2+ metastatic solid tumours.
Regulatory Analysis
Explore the FDA’s Competitive Generic Therapy Approvals page, offering insights into the program designed to encourage generic drug competition. Access information about approved CGT products and find resources, including a downloadable CGT approvals spreadsheet.
Supporting Context
- Therapeutic area
- Oncology · HER2-positive solid tumours
- Sub-indication
- HER2
Related signal: Enhertu recommended for EU approval in HER2+ metastatic solid tumours
Source
FDA document
View source